Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma

Seog Yun Park, Baek-Hui Kim, Jung Ho Kim, Sun Lee, Gyeong Hoon Kang

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Context. - Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult. Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites. Objective. - To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin. Design. - Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels. Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method. Results were validated using 60 cases of metastatic adenocarcinoma with known primaries. Results. - Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2 +/CK7-/CK20+ or TTF-1-/CDX2 +/CK7-/CK20-/(CEA+ or MUC2 +); ovarian, CK7+/MUC5AC+/TTF-1 -/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/ CK20- or ER+/TTF-1-/CDX2-/CK20 -/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP- 15-/ER-/CEA-/MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/CEA +/MUC5AC+; and stomach, TTF-1-/CDX2 +/CK7+/CK20-. Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75% of cases. Conclusions. - Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.

Original languageEnglish
Pages (from-to)1561-1567
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume131
Issue number10
Publication statusPublished - 2007 Oct 1
Externally publishedYes

Fingerprint

Adenocarcinoma
Carcinoembryonic Antigen
Estrogen Receptors
Stomach
thyroid nuclear factor 1
Fibrocystic Breast Disease
Keratin-7
Lung
Decision Trees
Proteins
Pancreatic Ducts
Bile Ducts
Neoplasms
Breast
Phenotype
Sensitivity and Specificity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. / Park, Seog Yun; Kim, Baek-Hui; Kim, Jung Ho; Lee, Sun; Kang, Gyeong Hoon.

In: Archives of Pathology and Laboratory Medicine, Vol. 131, No. 10, 01.10.2007, p. 1561-1567.

Research output: Contribution to journalArticle

Park, Seog Yun ; Kim, Baek-Hui ; Kim, Jung Ho ; Lee, Sun ; Kang, Gyeong Hoon. / Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. In: Archives of Pathology and Laboratory Medicine. 2007 ; Vol. 131, No. 10. pp. 1561-1567.
@article{9a0ad4ed8f0d416ba22200f9818db69a,
title = "Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma",
abstract = "Context. - Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult. Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites. Objective. - To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin. Design. - Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels. Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method. Results were validated using 60 cases of metastatic adenocarcinoma with known primaries. Results. - Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2 +/CK7-/CK20+ or TTF-1-/CDX2 +/CK7-/CK20-/(CEA+ or MUC2 +); ovarian, CK7+/MUC5AC+/TTF-1 -/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/ CK20- or ER+/TTF-1-/CDX2-/CK20 -/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP- 15-/ER-/CEA-/MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/CEA +/MUC5AC+; and stomach, TTF-1-/CDX2 +/CK7+/CK20-. Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75{\%} of cases. Conclusions. - Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.",
author = "Park, {Seog Yun} and Baek-Hui Kim and Kim, {Jung Ho} and Sun Lee and Kang, {Gyeong Hoon}",
year = "2007",
month = "10",
day = "1",
language = "English",
volume = "131",
pages = "1561--1567",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "10",

}

TY - JOUR

T1 - Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma

AU - Park, Seog Yun

AU - Kim, Baek-Hui

AU - Kim, Jung Ho

AU - Lee, Sun

AU - Kang, Gyeong Hoon

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Context. - Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult. Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites. Objective. - To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin. Design. - Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels. Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method. Results were validated using 60 cases of metastatic adenocarcinoma with known primaries. Results. - Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2 +/CK7-/CK20+ or TTF-1-/CDX2 +/CK7-/CK20-/(CEA+ or MUC2 +); ovarian, CK7+/MUC5AC+/TTF-1 -/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/ CK20- or ER+/TTF-1-/CDX2-/CK20 -/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP- 15-/ER-/CEA-/MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/CEA +/MUC5AC+; and stomach, TTF-1-/CDX2 +/CK7+/CK20-. Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75% of cases. Conclusions. - Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.

AB - Context. - Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult. Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites. Objective. - To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin. Design. - Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels. Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method. Results were validated using 60 cases of metastatic adenocarcinoma with known primaries. Results. - Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2 +/CK7-/CK20+ or TTF-1-/CDX2 +/CK7-/CK20-/(CEA+ or MUC2 +); ovarian, CK7+/MUC5AC+/TTF-1 -/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/ CK20- or ER+/TTF-1-/CDX2-/CK20 -/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP- 15-/ER-/CEA-/MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/CEA +/MUC5AC+; and stomach, TTF-1-/CDX2 +/CK7+/CK20-. Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75% of cases. Conclusions. - Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.

UR - http://www.scopus.com/inward/record.url?scp=35348931111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348931111&partnerID=8YFLogxK

M3 - Article

C2 - 17922593

AN - SCOPUS:35348931111

VL - 131

SP - 1561

EP - 1567

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 10

ER -